ORIGINAL ARTICLE

original article

Diabetes, Obesity and Metabolism 18: 812–819, 2016. © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin H. W. Rodbard1 , J. Seufert2 , N. Aggarwal3 , A. Cao4 , A. Fung4 , M. Pfeifer5 & M. Alba4 1 Endocrine and Metabolic Consultants, Rockville, MD, USA 2 Department of Endocrinology and Diabetology, Clinic for Internal Medicine II, University Medical Center, Freiburg, Germany 3 Aggarwal and Associates Ltd, Brampton, ON, Canada 4 Janssen Research & Development, LLC, Raritan, NJ, USA 5 Janssen Scientific Affairs, LLC, Raritan, NJ, USA

Aims: To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin. Methods: In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ≥70 ml/min/1.73 m2 ; fasting self-monitored blood glucose ≥5.6 mmol/l (≥100 mg/dl); and no volume depletion–related adverse events (AEs) within 2 weeks before dose increase. Endpoints included change in glycated haemoglobin (HbA1c) at week 26 (primary); proportion of patients achieving HbA1c 270 mg/dl) after day 1 up to week 6, SMBG >13.3 mmol/l (>240 mg/dl) after week 6 up to week 12, and SMBG >11.1 mmol/l (>200 mg/dl) after week 12 up to week 26; values were confirmed with a central laboratory fasting plasma glucose (FPG) measurement]. This study was conducted in accordance with the ethical principles that comply with the Declaration of Helsinki and was consistent with Good Clinical Practice and applicable regulatory requirements. Approval was obtained from institutional review boards and independent ethics committees for each

Volume 18 No. 8 August 2016

participating centre. Patients provided informed written consent before participation.

Randomization, Blinding and Titration Patients were randomized (1 : 1) to receive canagliflozin 100 mg or placebo once daily using a computer-generated randomization schedule prepared by or under supervision of the sponsor prior to initiation of the study (Figure 1). Randomization was balanced using permuted blocks and stratified by HbA1c at screening (HbA1c

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.

To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus ...
328KB Sizes 0 Downloads 14 Views

Recommend Documents


Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
Previous randomized controlled trials (RCTs) have reported conflicting results for the efficacy of sitagliptin and sulfonylurea therapy in patients with type 2 diabetes mellitus showing inadequate glycemic control with metformin monotherapy. To clari

Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.
Currently available antihyperglycemic agents (AHAs), despite being effective, do not provide adequate glycemic control in some cases and are associated with side effects. A sodium glucose co-transporter 2 inhibitor, canagliflozin, is a newer AHA, whi

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
This post hoc analysis evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) from Latin America.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhi

Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU trial).
Evaluation of: Cefalu WT, Leiter LA, Yoon KH et al. Efficacy and safety of canagliflozin versus glimepiride in patients with Type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week results from a randomized, double-blind, Phase I

Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
The aim of the present study was to evaluate the long-term efficacy and safety of adding repaglinide in patients with type 2 diabetes mellitus whose blood glucose levels were not sufficiently controlled by treatment with a dipeptidyl peptidase-4 inhi

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone.

Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.
Metformin is a preferred drug for starting treatment in type 2 diabetes mellitus. But, eventually most of the patients need additional drug to control blood sugar level. The choice of drug depends upon several factors including patient specific crite

Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
To evaluate the safety and efficacy of metformin in patients with type 2 diabetes mellitus (T2DM) and chronic hepatitis C virus (HCV) with or without cirrhosis and hepatocellular carcinoma (HCC).